FTSE MIB
33.939,75 -331,37 (-0,97%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
84,11 +0,54 (+0,65%) Bitcoin EUR
59.896,48 -9,85 (-0,02%)
Galectin Therapeutics Inc. (GALT)
Dopo ore:
| Chiusura precedente | 3,2900 |
| Aperto | 2,9900 |
| Denaro | 3,4800 x 500 |
| Lettera | 3,5500 x 400 |
| Min-Max giorno | 3,2000 - 3,5500 |
| Intervallo di 52 settimane | 1,2800 - 4,2700 |
| Volume | |
| Media Volume | 153.167 |
| Capitalizzazione | 216,663M |
| Beta (5 anni mensile) | 0,88 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7400 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireGalectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the company’s board of directors. Dr. Carson has served as a senior advisor to Galectin Therapeutics since 2021. In this role, he has increased awareness of Galectin’s ongoing Phase 2b/3 NAVIGATE clinical trial in cirrhosis caused by nonalcoholic steatohepati
- GlobeNewswire
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis. NAVIGATE is the first study of its kind and is a global effort that randomize
- GlobeNewswire
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session. The presentation, titled “Targeting Activated Macrophages
